
Pulse Biosciences PLSE
$ 21.57
1.27%
Annual report 2025
added 02-19-2026
Pulse Biosciences Deferred Revenue 2011-2026 | PLSE
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Pulse Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 16 K | - | - | - | - | - | - | 39.5 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.5 K | 16 K | 27.7 K |
Quarterly Deferred Revenue Pulse Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 4 K | - | 38 K | 32 K | 16 K | 16 K | 7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38 K | 4 K | 18.8 K |
Deferred Revenue of other stocks in the Medical instruments industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AngioDynamics
ANGO
|
200 K | $ 10.6 | -1.03 % | $ 433 M | ||
|
Luminex Corporation
LMNX
|
21.1 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
59.8 K | - | -9.52 % | $ 20.6 M | ||
|
Harvard Bioscience
HBIO
|
4.51 M | $ 0.47 | -4.15 % | $ 19.9 M | ||
|
Alcon
ALC
|
581 M | $ 77.32 | -1.5 % | $ 40.4 B | ||
|
Antares Pharma, Inc.
ATRS
|
3.94 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
26.2 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
26.8 K | - | - | $ 282 M | ||
|
ICU Medical
ICUI
|
33.8 M | $ 125.85 | -2.28 % | $ 3.1 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
110 M | - | -0.05 % | $ 10.3 B | ||
|
iRhythm Technologies
IRTC
|
4.2 M | $ 113.0 | -1.46 % | $ 3.62 B | ||
|
Intuitive Surgical
ISRG
|
507 M | $ 472.16 | -1.48 % | $ 169 B | ||
|
The Cooper Companies
COO
|
128 M | $ 69.92 | -2.24 % | $ 13.9 B | ||
|
Varian Medical Systems, Inc.
VAR
|
782 M | - | -0.02 % | $ 16.3 B | ||
|
Haemonetics Corporation
HAE
|
43.3 M | $ 59.92 | 0.72 % | $ 3.02 B | ||
|
Masimo Corporation
MASI
|
95.5 M | $ 175.49 | -0.01 % | $ 9.35 B | ||
|
Predictive Oncology
POAI
|
305 K | - | - | $ 31.1 M | ||
|
Ekso Bionics Holdings
EKSO
|
1.73 M | $ 11.56 | -2.12 % | $ 28 M | ||
|
Repro Med Systems
KRMD
|
125 K | $ 4.28 | -0.7 % | $ 198 M | ||
|
Baxter International
BAX
|
141 M | $ 17.4 | -3.36 % | $ 8.93 B | ||
|
BioLife Solutions
BLFS
|
103 K | $ 18.36 | 1.16 % | $ 846 M | ||
|
Nephros
NEPH
|
70 K | $ 3.5 | -7.89 % | $ 36.4 M | ||
|
ResMed
RMD
|
109 M | $ 230.84 | -0.68 % | $ 33.7 B | ||
|
Retractable Technologies
RVP
|
377 K | $ 0.71 | 2.62 % | $ 21.3 M | ||
|
NeuroMetrix
NURO
|
1.96 M | - | 5.05 % | $ 9.02 M | ||
|
Merit Medical Systems
MMSI
|
572 K | $ 69.95 | 2.61 % | $ 4.14 B | ||
|
Envista Holdings Corporation
NVST
|
185 M | $ 24.61 | -3.26 % | $ 4.13 B | ||
|
STAAR Surgical Company
STAA
|
3.75 M | $ 18.84 | 2.45 % | $ 934 M | ||
|
Stereotaxis
STXS
|
5.68 M | $ 1.89 | 0.27 % | $ 172 M | ||
|
OraSure Technologies
OSUR
|
1.52 M | $ 2.97 | -3.88 % | $ 218 M | ||
|
LeMaitre Vascular
LMAT
|
552 K | $ 108.06 | 1.43 % | $ 2.45 B | ||
|
Pro-Dex
PDEX
|
202 K | $ 48.46 | 3.5 % | $ 159 M | ||
|
Microbot Medical
MBOT
|
16.8 K | $ 2.69 | -1.47 % | $ 27.4 M | ||
|
West Pharmaceutical Services
WST
|
51.9 M | $ 235.46 | 1.89 % | $ 17 B | ||
|
Repligen Corporation
RGEN
|
17.1 M | $ 114.2 | 0.39 % | $ 6.36 M | ||
|
DENTSPLY SIRONA
XRAY
|
74 M | $ 11.54 | -2.2 % | $ 2.3 B | ||
|
STERIS plc
STE
|
160 M | $ 214.57 | 1.05 % | $ 21.2 B | ||
|
Milestone Scientific
MLSS
|
340 K | $ 0.28 | -3.75 % | $ 22.3 M |